May 19, 2021
Via: PharmaphorumIt’s not uncommon for drug developers put a positive spin on lacklustre clinical data, but CytoDyn’s attempts seems to have irritated the US regulator, specifically relating to its use of subgroup analyses to try to indicate a benefit for leronlimab. […]
September 26, 2023
September 21, 2023
September 19, 2023
September 14, 2023
September 7, 2023
September 1, 2023
September 19, 2023
September 5, 2023